CLINICAL_TRIALS
trial_result
· 2023-10-25
Clinical Trial Update: MabionCD20 Compared to MabThera in Lymphoma Patients [Phase 3]
Summary
A Phase 3 trial comparing MabionCD20 to MabThera in patients with diffuse large B-cell lymphoma has completed and results were posted in 2023.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Mabion SA | Conditions: Diffuse Large B-Cell Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2023-10-25